Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

• Status: Recruiting
• Trial end date: 2025-12-01

Summary

Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).

• Phase: Phase 3

Details

• Lead Sponsor: ISU Abxis Co., Ltd.